



**Assisted Living
Alberta**

**Calgary Type A Continuing Care Home Formulary
Formulary Highlights
March 31, 2026
Page 1 of 7**

Calgary Type A Continuing Care Home (CCH) Formulary

Formulary Highlights: March 31, 2026

[Calgary Zone Type A CCH Formulary Highlights \(albertahealthservices.ca\)](http://albertahealthservices.ca)

Calgary Type A CCH Pharmacy & Therapeutics Committee



Contents

March 2026.....	3
Formulary Changes (Additions, Changes, Deletions)	3
Other Formulary Updates.....	3
November 2025.....	4
Formulary Changes (Additions, Changes, Deletions)	4
Other Formulary Updates.....	4
September 2025	4
Formulary Changes (Additions, Changes, Deletions)	4
Other Formulary Updates.....	5
July 2025	5
Formulary Changes (Additions, Changes, Deletions)	5
Other Formulary Updates.....	6
Feb 2025	6
Formulary Changes (Additions, Changes, Deletions)	6
Other Formulary Updates.....	7

March 2026

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) listing changes to the Calgary Zone Type A CCH Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

Product Description	Strength (Dosage Form)	Route of Administration	Listing / Comments
clozapine	12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg (oral disintegrating tablets)	oral	Added to Restricted Use (RS)
dantrolene sodium	100 mg	oral	Strength delisted (product discontinuation)
NanoSalv	any size	topical	Not a benefit; not eligible for Non-Formulary funding

Other Formulary Updates

- **Calgary Zone Type A CCH Pharmacy Service Provider** [Contact List](#) – updated
- **Formulary Policy and Procedures**
 - FPP-01 **Formulary Rationale** *New*
 - FPP-02 **Criteria for Listing Drug Products on the Formulary** *New*
 - FPP-02a **Requests for Additions, Deletions or Changes to the Formulary FORM** *New*
 - FPP-03 **Non-Formulary Drugs Requests** *New*
 - FPP-03a **Non-Formulary Drug Request FORM** *Updated*
 - **Transitional Medication Supply from Acute Care to Long Term Care** - *Rescinded*
- **Formulary Medication Listing**
 - The [Full Formulary Listing](#) was updated to reflect the changes in the above table.
- **Restricted Use Medications**
 - [Restricted Use Medications – Miscellaneous Drugs](#) (RS-11) – clozapine ODT added.
- **Automatic Substitution**
 - [ASL-01 Automatic Substitution](#) – overview updated.

November 2025

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) listing changes to the Calgary Zone Type A CCH Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

Product Description	Strength (Dosage Form)	Route of Administration	Listing / Comments
ursodiol, ursodeoxycholic acid (Urso)	250 mg and 500 mg (tablet)	oral	added to Formulary (F – open listing)
montelukast (Singulair)	10 mg (tablet)	oral	added to Formulary (F – open listing)

Other Formulary Updates

- **Formulary Medication Listing**
 - The [Full Formulary Listing](#) was updated to reflect the changes in the above table.

September 2025

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) listing changes to the Calgary Zone Type A CCH Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

Product Description	Strength (Dosage Form)	Route of Administration	Listing / Comments
ezetimibe (Ezetrol)	10 mg (tablets)	oral	added to Formulary (F - open listing)
tranexamic acid (Cyklokapron)	500 mg (tablets)	oral	added to Formulary (F - open listing)
sucralfate (Sulcrate)	1 g (tablets)	oral	added to Restricted Use (RS)
sucralfate (Sulcrate)	200 mg/mL (suspension)	oral	added to Restricted Use (RS)
betaxolol (Betoptic S)	0.25% (eye drops)	ophthalmic	delisted (product discontinuation)
zinc sulfate (Anusol)	0.5% (ointment)	topical	include in Wardstock list (optional)



carboxymethylcellulose / electrolytes (Moi-Stir Spray)	(solution)	topical mouth spray	include in Wardstock list (optional)
--	------------	------------------------	---

Other Formulary Updates

- **Formulary Policy and Procedures**

- **Wardstock/Statbox Lists**

- Moi-Stir spray and Zinc sulfate 0.5% rectal ointment added to [Wardstock and Statbox List](#) – optional listings. The pharmacy provider and home should discuss the optional addition to the site's wardstock at the home's medication management committee meeting.

- **Formulary Medication Listing**

- The [Full Formulary Listing](#) was updated to reflect the changes in the above table.

- **Restricted Use Medications**

- [Restricted Use Medications – Miscellaneous Drugs](#) (RS-11)

- **sucralfate 1 g oral tablets** added to formulary with the following restrictions:
For treatment or prophylaxis of gastric ulcers, duodenal ulcers, or GERD refractory to proton-pump inhibitors and/or histamine H2 antagonists.
*Treatment dosing (**four times a day**) is restricted to **up to 8 weeks**. For use beyond 8 weeks, prophylaxis dosing (**twice a day**) is funded.*
 - **sucralfate 200 mg/mL oral suspension** added to formulary with the following restrictions:
For treatment or prophylaxis of gastric ulcer, duodenal ulcers, or GERD refractory to proton-pump inhibitors and/or histamine H2 antagonists; AND
 - i. when the resident cannot swallow crushed tablets; OR
 - ii. when diagnostic imaging shows significant esophageal involvement.*Treatment dosing (**four times a day**) is restricted to **up to 8 weeks**. For use beyond 8 weeks, prophylaxis dosing (**twice a day**) is funded;*

July 2025

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) listing changes to the Calgary Zone Type A CCH Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

Product Description	Strength (Dosage Form)	Route of Administration	Listing / Comments
Acetylsalicylic acid (Aspirin, ASA)	81 mg OR 80 mg (chewable)	Oral	chewable strength (80 mg vs 81 mg) selection depends on the pharmacy provider's LCA

Other Formulary Updates

- **Formulary Policy and Procedures**
 - **Wardstock/Statbox Lists**
 - Basalglar listing was removed from [Wardstock and Statbox List](#). Semglee is listed as the glargine option.
- **Formulary Medication Listing**
 - The [Full Formulary Listing](#) was updated to reflect the changes in the above table.

Feb 2025

Formulary Changes (Additions, Changes, Deletions)

The following drug product(s) listing changes to the Calgary Zone Type A CCH Formulary are complete. When available, consider the lowest cost alternative (LCA) product the benefit.

Product Description	Strength (Dosage Form)	Route of Administration	Listing / Comments
famotidine	10 mg, 20 mg & 40 mg tablets	oral	removed temporarily status and made a regular Formulary listing
dapagliflozin	5 mg & 10 mg tablets	oral	moved from Special Authorization to regular Formulary listing
dapagliflozin / metformin	5 mg*1000 mg & 5 mg*850 mg tablets	oral	moved from Special Authorization to regular Formulary listing
Semglee [®] (insulin glargine)	100 unit/mL pre-filled pen (3mL)	Injection	added to formulary as preferred LCA for glargine, added an Automatic Substitution

			(ASL-1), added to Statbox list (optional)
Basaglar [®] (insulin glargine)	100 unit/mL pre-filled pen (3mL)	Injection	delisted from formulary as of May 31, 2025, see Automatic Substitution (ASL-01) *Temporarily covered until May 31, 2025 for transitioning*

Other Formulary Updates

- **Formulary Policy and Procedures**
 - [FPP-10 Compound Coverage Criteria](#) was updated, including the form. The FPP-10 form will be distributed to the contracted pharmacy providers by email.
 - [FPP-13 Biosimilar Initiative](#) was updated.
 - **Position Statements & Guidance**
 - [Botulinum Toxin A Guidance](#) was added to the
 - **Wardstock/Statbox Lists**
 - [Wardstock and Statbox List](#) was updated to reflect the insulin glargine change.
- **Formulary Medication Listing**
 - The [Full Formulary Listing](#) was updated to reflect the changes in the above table.
- **High Cost/Special Authorization**
 - [SA-30 SGLT-2 Inhibitors and DPP-4 Inhibitors](#) was updated to reflect the listing change to dapagliflozin (now open formulary listing), and an evaluation of the risk of urogenital infections was added to the assessment section. The SA-30 will be distributed to the contracted service providers by email.
- **Automatic Substitution**
 - [ASL-01 Automatic Substitution List-01](#) was updated with the Semglee (insulin glargine) automatic substitution.